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Abstract
Independent research groups reported that DING protein homologues isolated from bacterial, plant and human cells
demonstrate the anti-HIV-1 activity. This might indicate that diverse organisms utilize a DING-mediated broad-range
protective innate immunity response to pathogen invasion, and that this mechanism is effective also against HIV-1. We
performed structural analyses and evaluated the anti-HIV-1 activity for four DING protein homologues isolated from
different species. Our data show that bacterial PfluDING, plant p38SJ (pDING), human phosphate binding protein (HPBP)
and human extracellular DING from CD4 T cells (X-DING-CD4) share high degrees of structure and sequence homology.
According to earlier reports on the anti-HIV-1 activity of pDING and X-DING-CD4, other members of this protein family from
bacteria and humans were able to block transcription of HIV-1 and replication of virus in cell based assays. The efficacy
studies for DING-mediated HIV-1 LTR and HIV-1 replication blocking activity showed that the LTR transcription inhibitory
concentration 50 (IC50) values ranged from 0.052–0.449 ng/ml; and the HIV-1 replication IC50 values ranged from 0.075–
0.311 ng/ml. Treatment of cells with DING protein alters the interaction between p65-NF-kB and HIV-1 LTR. Our data
suggest that DING proteins may be part of an innate immunity defense against pathogen invasion; the conserved structure
and activity makes them appealing candidates for development of a novel therapeutics targeting HIV-1 transcription.
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Introduction
DING proteins were recently clustered into a new group of
highly conserved proteins found in prokaryotes and eukaryotes
throughout the plant and animal kingdoms [1,2,3,4,5,6,7].
Phylogenetically, the DING proteins belong to the superfamily
of phosphate-binding proteins (PBP) which comprises also PstS
and alkaline phosphatase (AP), both exclusively found in
prokaryotes [8]. To date, more than fifty different DING proteins
have been reported in all kingdoms of life [9]; however, their
complete genomic structure and chromosomal assignment in
humans is still unknown.
Structural studies on the human phosphate binding protein
(HPBP) and the DING protein from Pseudomonas fluorescens
(PfluDING) revealed interesting details about their configuration
[10,11]. Similarly to the PstS, the DING proteins are formed by
two globular domains linked together by a flexible hinge allowing
a ‘‘Venus flytrap’’ movement [12]. However, the structural
differences on four external loops and presence of two disulfide
bridges in DINGs stand them apart from other PBPs and suggest
an autonomous class of proteins [12]. The phosphate molecule in
the DING protein resides in the vicinity of the binding cleft formed
by the two globular domains. The binding of this phosphate ion
occurs between four conserved residues in each globular domain,
that form a complex network of 12 hydrogen bonds [11]. It has
been shown that presence of an aspartic acid (D62) in this
phosphate-binding pocket is important for the distinction between
the phosphate and other closely-related ions such as sulfate or
arsenate [13,14].
The biology of eukaryotic DING proteins as a group remains to
be defined, but most DING proteins isolated from eukaryotes were
related to a broad range of disorders and biological processes
[1,2,6,7,15,16,17]. For example, the synovial stimulatory protein
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(SSP) has the capacity to induce proliferation of the peripheral
blood T cells in patients with rheumatoid arthritis [6]. Another
DING protein, the steroidogenesis-Inducing protein (SIP) has
mitogenic activity toward the ovarian epithelium and might be
involved in the etiology of ovarian cancer [18]. In contrast, a
recent report by Hendriks et al indicated that dysfunction of the
newly-characterized bovine DING homologue, the gonadotropin
surge-Inhibiting/attenuating factor (GnSIF/AF) could lead to
polycystic ovarian syndrome [15]. The crystal adhesion inhibitor
(CAI), found in monkey and in human renal epithelial cells, has
been shown to inhibit the growth of kidney stones [16]. Finally,
several members of the DING family inhibit HIV-1 replication
through blockage of the LTR transcriptional activity [4,7,19,20].
This comprises HPBP from human plasma [19], X-DING-CD4
from CD4+ T cells [7,21] and p27SJ (and its full-length form,
p38SJ) from the medicinal plant Hypericum perforatum [4,20].
It has been shown that primary target for X-DING-CD4 in
blocking HIV-1 activity was NF-kB [22,23] whereas p38SJ, called
hereafter pDING, exhibits the ability to interact with C/EBPb and
Tat, and dephosphorylates the CTD domain of the RNA
polymerase II. All these interactions can participate in anti-HIV-
1 activity of DING proteins [4,20,24]. Subsequent studies showed
the ability of pDING and X-DING-CD4 in regulating various
cellular genes including MCP-1 and IL-8 by either C/EBPb- and/
or NF-kB-dependent pathways [25,26]. In addition to the in vitro
studies, the clinical evaluations indicated that HIV-infected
patients have an increased concentration of DING proteins [27],
and the increased expression of the X-DING-CD4 mRNA
correlates with the cellular restriction of HIV-1 replication in
human macrophages [21].
The NF-kB system is involved in the immediate signaling
mechanisms of the innate immunity responses against infecting
pathogens, including HIV-1 [28]. Activation of NF-kB-dependent
transcription of cytokines and other mediators of inflammation
exerts protective anti-microbial function. Transcription of several
viruses such as Herpes Simplex Virus (HSV), Simian Virus 40
(SV40) and HIV-1 depends on NF-kB signaling [29]. The anti-
NF-kB activity of DING proteins is of particular interest in the
design of novel anti-viral therapies.
The conserved nature and anti-HIV-1 properties of these
DING homologues indicate their function as innate immunity
effector molecules and highly recommend consideration of DING
proteins as a potential antiretroviral. With this in mind, we
performed structural analyses and anti-HIV-1 activity studies for
four DING homologues isolated from cells of Pseudomonas fluorescens
(PfluDING), Hypericum perforatum (pDING) and Homo sapiens (HPBP
and X-DING-CD4). To date, HPBP represent the only DING
protein for which a dose response and cytotoxicity assays have
been performed [19]. We applied cell-based assays to probe the
therapeutic efficacy of DING proteins to block the HIV-1 LTR
and virus replication, and calculated the inhibitory concentration
50 (IC50). Based on the previous reports showing that the human
X-DING-CD4 blocked the p50/p65 NF-kB/HIV-1 LTR binding
[22,30,31], we employed a chromatin immunoprecipitation (ChIP)
assay to observe the recruitment of p50/p65 NF-kB dimer to
HIV-1 LTR promoter in cells exposed to treatment by all tested
DING homologues.
Materials and Methods
The studies reported here using human peripheral blood
lymphocytes were granted exempt status by the St. Luke’s-
Roosevelt Institutional Review Board under qualifications listed in
section 45.101 (b) (4).
Cell cultures and reagents
Human astrocytoma U87 MG and MAGI-CCR-5 [32] cell
lines were obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). The 1G5 cells stably expressing a
luciferase gene driven by the HIV-1 long terminal promoter (LTR)
[33] were obtained through the NIH AIDS Research and Reagent
Program Division of AIDS, NIAID. The U87 MG and MAGI-
CCR-5 cells were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS; Life Technologies, Inc.), antibiotics (100 U/ml penicillin
and 10 mg/ml streptomycin) and glutamate, while the 1G5 cells
were cultured in RPMI 1640 (Sigma) supplemented with 5% FBS,
antibiotics and glutamate. Peripheral blood lymphocytes (PBLs)
were obtained by elutriation from the whole blood of healthy,
HIV-1 negative volunteers. Before the experiment, cells were
stimulated for 2 days in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS),
phytohemaglutinin (PHA, 5 mg/ml; Sigma), interleukin 2 (10 U/
ml; R&D Systems), antibiotics and glutamate. Subsequently, cells
were cultured without PHA. All cell cultures were incubated at
37uC in a 7% CO2 95% air-humidified incubator.
DING proteins
The detailed information referring to the isolation and
purification of X-DING-CD4, HPBP and pDING was previously
reported [4,7,10,34]. PfluDING protein was used in the form of a
site-specific mutation (S32G), altering one of the phosphate-
binding residues, and resulting in a protein purified by the same
method as the wild-type protein [34]. For evaluations of the
biological activity, all four DING homologues were dialyzed
against 10 mM Tris-HCl, pH 8.0 using benzoylated cellulose
tubing with an MW cut-off of 1.2 kDa (Sigma). Subsequently the
dialyzed material was concentrated by lyophilization and stored at
4uC.
Tertiary structure prediction
Sequences of DING proteins (NCBI Accession Number:
AAW57408, ADT62916, YP_002872202.1 and P85173.1 for
pDING, X-DING-CD4, PfluDING and HPBP) have been aligned
using ClustalW 2.1 [35]. The structure of X-DING-CD4 and
pDING was related to sequences of HPBP and PfluDING as a
template. Structure alignment was performed by MODELLER
9.11 software [36]. Heteroatoms of pdb files have been removed
except the phosphate molecule on the PfluDING structure. The
3D structures were validated using RAMPAGE software [37].
Pymol was used to represent DING protein structures [38].
SDS PAGE
A total of 50 ng of each DING protein sample was resolved by
SDS-PAGE and transferred to supported nitrocellulose mem-
branes as described previously [4]. Proteins were visualized by
Coomassie brilliant blue or by western blot using rabbit polyclonal
antibody to pDING with the enhanced chemiluminescence
detection system (Amersham Pharmacia). Antibody specific for
pDING (anti-p27SJ rabbit polyclonal antibody) was obtained from
Lampire Biological Laboratories, Inc. Pipersville, PA.
ChIP assay
The U87 MG cells were transfected using the FuGENE 6
transfection reagent (Roche). Briefly, 16106 cells were cultured
overnight in 100 mm plates. Subsequently, cells were transfected
with 1 mg of pGL3-Luc LTR plasmid in the presence of 200 ng/
ml of each DING protein, respectively. The pGL3-Luc LTR
DING Proteins Inhibit Transcription of HIV-1 LTR
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plasmid used for the chromatin immunoprecipitation (ChIP) assay
was generated from the HIV-1 LTR (2374/+43bp) DNA
fragment cloned into the pGL3-basic vector (Promega), as we
described before [4]. At 48 hours post-transfection, proteins were
cross-linked with 1% formaldehyde for 10 min at 37uC; then cells
were washed twice in ice-cold PBS supplemented with 1 mM
phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml aprotinin and
1 mg/ml pepstatin A, and pelleted for 4 min at 2000 rpm at 4uC.
The cell pellets were lysed in 200 ml of lysis buffer (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 0.1% Nonidet P-40 and protease
inhibitors as above) for 10 min on ice. Subsequently, cell lysates
were sonicated to shear the genomic DNA to fragments between
200 and 1000 bp, cleared by centrifugation for 10 min at
13,000 rpm at 4uC, and the supernatant was diluted 10-fold in
ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl). To remove
the nonspecific background, all protein extracts were pre-cleared
with 80 ml of salmon sperm DNA/protein A agarose-50% slurry
for 30 min at 4uC. For the IP reaction, 250 mg of each protein
sample was incubated overnight at 4uC with 2 ml of anti-p65 NF-
kB (F-6) antibody (Santa Cruz Biotechnology) or 2 ml of control
normal mouse serum (Pierce Chemical). The IP complexes were
precipitated by addition of 60 ml of salmon sperm DNA/protein A
agarose slurry for 1 hour at 4uC and collected by centrifugation at
1000 rpm at 4uC. Following washing for 3–5 min at room
temperature (RT) with 1 ml of low salt immune complex wash
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, pH 8.1, 150 mM NaCl), high salt immune complex wash
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, pH 8.1, 500 mM NaCl), LiCl immune complex wash buffer
(0.25 M LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM
EDTA, 10 mM Tris-HCl, pH 8.1), and 1X TE buffer, the IP
complexes were eluted for 15 min with the elution buffer (Tris-
HCl, 1 mM EDTA, pH 8.0). The antibody/protein/LTR cross-
linking was reversed by incubation with 8 ml 5 M NaCl at 65uC
for 4 hours. Proteins were digested in 10 ml of 0.5 M EDTA, 20 ml
1 M Tris-HCl, pH 6.5 and 2 ml of 10 mg/ml Proteinase K for
1 hour at 45uC and DNA was recovered by phenol/chloroform
extraction and ethanol precipitation. The immunoprecipitated
HIV-1 LTR was detected by PCR amplification with primers
flanking the NF-kB region as follows: sense 59-(-374)-TTTGCA-
GAACTACACACCAGGGC C-(-351)-39 and antisense 59-(-75)-
CTCCCTGGAAAGTCCCCAGCGGAA)-(-98)-39. The DNA
fragments were analyzed in 2% agarose gel and subjected to
band densitometry.
Rapid Suppression Assay (RSA)
RSA was performed essentially as described before [30]. Briefly,
1G5 cells, stably transfected with an inducible luciferase gene
driven by HIV-1 LTR [33], were washed in PBS, and resuspended
in hybridoma medium to a concentration of 56106 cells/ml. For
control titration curves, 100 ml aliquots of 1G5 cells were
supplemented with increasing amounts of DING proteins, control
C3 Peptide P16 or medium alone, brought to a final volume of
200 ml and incubated for 3 hours at 37uC. The C3 Peptide P16 is
derived from the C3d component of serum complement; it
regulates B cells, but not T cells, through interacting with the
gp140 C3d receptor (CR2) [39]. Subsequently, cells were induced
with phorbol myristate acetate (PMA; Sigma; 5 ng/ml). Two
control tubes containing 1G5 cells were resuspended in hybridoma
medium (Invitrogen), with or without PMA. Three hours later cells
were lysed using reporter lysis buffer (Promega). Luciferase protein
expression was measured according to the manufacturer’s
protocol. All data were normalized by total protein concentration
measured by protein assay (Bio-Rad). The HIV-LTR inhibition
values were established from the formula: [(LUC1-LUC0)x100/Z]-
100; where LUC1 is the value obtained from PMA-induced cells
treated with a specific dilution of DING protein, and LUC0 is the
basal value obtained from uninduced, untreated cells; Z is the
absolute luciferase induction by PMA calculated as Z=LUCmax-
LUC0, where LUCmax is the value of 100% luciferase expression
in PMA-induced, untreated cells.
MAGI assay
The MAGI assay [32] was performed with modifications as
described before [7]. Briefly, MAGI-CCR-5 cells were seeded
24 hours prior to assay in a 96-well plate (Costar Scientific) at
6.26103 cells per well in DMEM supplemented with 10% fetal
bovine serum, antibiotics and glutamate (all from Sigma).
Subsequently, cells were exposed to DING protein or control
C3 Peptide P16 treatments. Twenty four hours later cells were
infected with 0.1 pg/cell NL4-3 HIV-1 isolate [40]. Replication of
virus was evaluated 48 hours later after fixation of cells with 1%
formaldehyde and 0.2% glutaraldehyde in PBS. The expression of
b-galactosidase was visualized by 50 min exposure to X-GAL (5-
bromo-4-chloro-3-indolyl-b-D-galactopyranoside), 0.4 mg/ml
2 mM MgCl2, 4 mM potassium ferricyanide at 37uC. After
enumeration of the infected (blue) cells, all cells were lysed and
subjected to the protein assay (Bio-Rad) to establish total protein
sample concentration, and all data were normalized by total
protein concentration. The values for inhibition of HIV-1
replication were calculated based on the formula [(R1–R0)x100/
Z]-100, where R1 is the value obtained from cells infected by HIV-
1 and treated with a specific dilution of DING protein and R0 is
the basal value obtained from the uninfected, untreated cells; Z is
the absolute HIV-1 replication value calculated as Z=Rmax-R0,
where Rmax is the value representing 100% of HIV-1 replication in
the untreated cells.
The IC50 values were calculated from titration curves using two
adjoining dilutions for each DING protein that showed inhibition
close to 50% inhibition of LTR (RSA) or HIV-1 replication
(MAGI).
Evaluation of DING protein-mediated antiviral activity in
primary human cells
36106 PBLs/well in a 24-well plate (Costar Scientific) were
cultured in 1 ml RPMI medium supplemented with antibiotics,
glutamate and 1 mg/ml of each DING protein, respectively. Six
hours after the initial exposure to the DING treatments, the
culture medium was supplemented with 3%/Vol FBS. One day
after treatment, cells were infected with 0.01 pg/cell NL4-3 HIV-
1 isolate [40] and cultured as described above, except that the
concentration of FBS was adjusted to 5%/Vol. The experimental
control consisted of HIV-1-infected but untreated PBLs. Replica-
tion of virus was evaluated at five and seven days after infection by
Elisa assay of the intracellular HIV-1 p24 core antigen (Perkin
Elmer). The viability of cells was assessed by the dye exclusion
method [41] at 1, 2, 3, 5 and 7 days after DING treatments.
Results
The structure of DING proteins
As shown in Figure 1A, the four DING proteins migrated with
similar mobility of about 39 kDa. All of them are recognized by
antibody generated to pDING (Fig. 1B), and that seems to be due
to the high sequence identity shared by the four DING
homologues (Fig. 2).
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PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e69623
The only existing crystal structures of DING proteins were
derived from the HPBP [10] and the bacterial PfluDING [11]. We
used this information for prediction of the X-DING-CD4 and
pDING structures (Fig. 3). Our analysis showed that all tested
proteins share the same topology with closely-similar structures.
The protein backbone is perfectly superimposed between the four
DING proteins, particularly in the zone implicated in phosphate
binding (Fig. 3, sphere). The structural difference was noted only
in the length of protuberant loops, which generated a visible
disparity in some regions between the four DING proteins.
Testing the anti-HIV-1 therapeutic utility of DING protein
variants
Independent studies demonstrated that phylogenetically-distinc-
tive DING proteins might have similar HIV-1 blocking activity
[4,7,19]. To better understand the specific anti-viral characteristics
Figure 1. Testing the mobility of DING protein variants in SDS-PAGE. (A) Coomassie brilliant blue staining of SDS PAGE gel. The first and last
lanes correspond to the molecular weight marker (respectively Rainbow and ProSieve). Lanes 1–4 correspond to pDING, HPBP, X-DING-CD4, and
PfluDING. (B) Western Blot of DING proteins. The first lane corresponds to molecular weight marker (ProSieve), bands lower than 39 kDa in lane 4
indicate degradation products of PfluDING.
doi:10.1371/journal.pone.0069623.g001
Figure 2. The amino acid alignment for pDING, PfluDING, X-DING-CD4 and HPBP proteins. Accession numbers for each protein are
indicated between bars, identical residues are highlighted with black. The sequence alignment was done using Bioedit software.
doi:10.1371/journal.pone.0069623.g002
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of these DING proteins, we compared their antiviral potential in a
uniform experimental setting. We utilized the rapid suppression
assay (RSA) [30] which tests directly the inhibition of HIV-1
transcription, the MAGI assay which tests the inhibition of HIV-1
replication in a single cycle infection [32], and evaluated the
DING – mediated inhibition of HIV-1 infection in human PBLs.
As shown in Fig. 4A, HPBP, pDING, PfluDING and X-DING-
CD4 blocked transcription of HIV-1 LTR by 75% at concentra-
tions ranging from 0.1–1 mg/ml. The HIV-1 LTR IC50 for human
X-DING-CD4 and HPBP was 52 ng/ml and 449 ng/ml,
respectively (Fig. 4A and Table 1). The IC50 values for plant
pDING and bacterial PfluDING were 160 ng/ml and 254 ng/ml,
in that order (Fig. 4A and Table 1). Treatment of cells with control
C3 Peptide P16 had only a minor effect on HIV-1 LTR activity,
blocking its expression by 4–9%.
Similarly to the evaluations of DING-mediated inhibition of
HIV-1 LTR transcription, the MAGI assay showed that
replication of HIV-1 was also blocked by all tested DING protein
homologues (Fig. 4B). This data suggested that successful
inhibition of the LTR transcription also interrupted the subse-
quent stages of the HIV-1 life cycle. The IC50 values ranged from
75 ng/ml for X-DING-CD4 to 311 ng/ml for PfluDING (Fig. 4B
and Table 1). The IC50 for HPBP and pDING was calculated as
150 ng/ml and 101 ng/ml, respectively (Fig. 4B and Table 1).
The control C3 Peptide P16 had only a minor effect on HIV-1
replication, with 11% inhibition at the highest dose of 1 mg/ml.
The RSA and MAGI data reflected the direct effect of DING
proteins on HIV-1 LTR transcription and the replication of virus
in a single-cycle infection. To study DING-mediated restriction of
virus in the normal course of infection, we subjected HIV-1-
infected PBLs to DING treatments and measured replication of
virus five and seven days later, assessing the intracellular levels of
p24 core protein. As shown in Fig. 5 (bars – right axis), all DING
homologues blocked replication of HIV-1. Five days after
infection, the intracellular p24 core protein was lower by 6 to
10-fold in DING-treated samples as compared to the untreated
control. Seven days after infection, the X-DING-CD4 and
pDING treatments reduced replication of HIV-1 by 11-fold,
HPBP by 6-fold and PfluDING by 1.7-fold. It is important to note
that throughout the course of this experiment, the viability of cells
treated with DING protein variants was comparable to the
untreated sample, thus alleviating concerns of treatment-induced
cytotoxicity (Fig. 5 lines – left axis).
The HIV-1 LTR transcription is not targeted by any of the
currently-available antiviral therapies. Although the complete
mechanism of DING proteins is yet to be defined, the published
data indicate that X-DING-CD4, HPBP and pDING block the
HIV-1 at the level of LTR transcription [4,7,19,22,24,31], and
current investigation confirmed this LTR-blocking activity also for
the bacterial PfluDING variant (Fig. 4A).
In light of earlier results pointing to the potential involvement of
NF-kB in suppression of HIV-1 by X-DING-CD4 [22,30,31], we
focused our attention on examining whether the other DING
counterparts can interfere with binding of NF-kB to the LTR
DNA sequence. To this end, the human astrocytic cell line, U-
87MG, transduced with HIV-1 LTR plasmid, was exposed to
each DING protein variant at a concentration of 200 ng/ml; this
concentration exceeded the IC50 dose for the inhibition of HIV-1
LTR transcription and replication (Fig. 4A, B and Table 1). As
shown in Fig. 6A, the recruitment of p65-NF-kB to the HIV-1
LTR promoter was severely impaired in the presence of each
DING protein (lanes 6–10) as compared to the input DNA control
(lanes 1–5); the specificity of this reaction was compared to the
control mouse serum which was negative for detection of p65-NF-
kB/LTR complex (lanes 11–15). Based on the band densitometry
analysis (Fig. 6B), the pDING and HPBP blocked the p65-NF-kB/
HIV-1 LTR binding by 61.9 and 61.5%, respectively; while the X-
DING-CD4 and PfluDING inhibited formation of this complex by
62.9 and 62.3%, in that order. Overall these results confirmed the
previously-published observations for the X-DING-CD4- mediat-
ed inhibition of p65 NF-kB/LTR binding [22,31]; it also
demonstrated that three other DING protein homologues had
similar abilities to block HIV-1 LTR transcription in human cells.
Our previous reports indicate that X-DING-CD4 treatment did
not affect the p50/p65NF-kB nuclear translocation [22], therefore
reduction of p65 NF-kB/DNA binding shown in Fig. 6 is a result
of DING-mediated activity and not reduced concentration of
nuclear p65 NF-kB.
Discussion
The DING proteins form an intriguing family of biologically
active factors contributing to protective [7,15,16,27,42,43] or
possibly adverse [1,6] cellular functions. In this work we selected
four distinct members of the DING family to ascertain their
structural and functional properties with specific interest in their
anti-HIV-1 activity.
The structural studies indicated that four tested DING proteins
have highly-conserved protein backbones and differ in the length
of the protuberant loops. The perfect superimposition observed in
the phosphate-binding cleft confirmed that these proteins have
been specifically designed to bind a phosphate ion.
Figure 3. Structure superposition of the four different DING
proteins. Structure alignment for X-DING-CD4 and pDING was
modeled into to HPBP and PfluDING X-ray structures. The backbone
of PfluDING (pdb:2Q9T), HPBP (pdb:2V3Q), p38SJ (pDING) and X-DING-
CD4 is shown in green, cyan, magenta and yellow, respectively. The
phosphate molecule is marked by sphere.
doi:10.1371/journal.pone.0069623.g003
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The differences in the length of protuberant loops could be
connected to the various physiological functions attributed to
DING proteins and may be related to their specific protein/
protein interactions (PON1, NF-kB, Tat or C/EBPb)
[4,20,22,25,26,27,44,45]. Nevertheless, the native function of
DING proteins, and particularly pDING, is yet to be determined,
but plant DING proteins associate with germin-like proteins
(GLPs) [46] known to have multiple functions including pathogen
elicitation [47].
As a dose response assay has been performed only for HPBP in
a previous study [19], it was worthwhile to determine the IC50
values for all tested DING proteins in a single experiment. Our
result confirmed those previously obtained for HPBP; the value of
150 ng/ml obtained from this experiment for the inhibition of
HIV-1 replication was close to that published by Cherrier et al
(190 ng/ml) [19]. However, while IC50 values obtained for X-
DING-CD4, pDING and PfluDING corresponded closely for the
RSA and MAGI assays, this was not the case for the HPBP. We
think that that it may be due to the instability of this protein (E.C.
personal communication), since the value obtained with the
MAGI assay was significantly low and close to that obtained by
Cherrier et al [19]. This might also explain the results obtained in
primary human cells. Results from this study also permitted the
determination of an order of efficiency of DING proteins for HIV-
1 inhibition. In fact, all DING proteins do not inhibit HIV-1
similarly. We showed that X-DING-CD4 was the most potent
inhibitor of HIV-1 transcription and replication, followed by
HPBP and pDING approximately at the same level and finally by
PfluDING. This difference of HIV-1 inhibition efficiency is likely
to be related to a specific part of the DING sequence (or structure)
that needs to be determined. It also might be related to specific
posttranslational modifications, absent in bacterial DING. We
found both methylated and un-methylated (E68) forms of X-
Figure 4. Evaluation of pDING, PfluDING, X-DING-CD4 and HPBP therapeutic efficacy against HIV-1. Dose versus response was
calculated by GraphPad Prism version 5.00 for Windows. The efficacy of selected DING proteins to block HIV-1 LTR transcription was measured by RSA
(A); and to block HIV-1 replication was measured by MAGI (B). The C3 peptide P16 was used as a negative control. The results are representative of at
least three separate experiments.
doi:10.1371/journal.pone.0069623.g004
Table 1. The comparison of the IC50 values acquired from
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DING-CD4 protein during its purification from cell culture
supernatants [7].
Results from NF-kB binding assays indicated that the four
tested DING proteins are able to block the formation of the p65-
NF-kB/HIV-1 LTR complex. The NF-kB family is composed of
five proteins (p50, p52, p65, RelB and c-Rel) that form various
complexes of transcription factors involved in inflammation, cell
proliferation and immunity [48]. The activation of NF-kB may
occur in response to different stimuli, including bacterial and viral
infections, and is triggered via different pathways [48,49]. Out of
15 known NF-kB homo- and heterodimers formed in cells, the
p65/p50 NF-kB is most abundant [50], rapidly activated [51] and
most importantly, used by HIV-1 during LTR-transactivation
[52]. Densitometry analysis showed no significant differences in
the rate of inhibition between the four DING proteins that ranged
from 61.5 to 62.9%. This result indicates that all tested DING
proteins inhibit NF-kB binding to LTR similarly when used at
concentrations exceeding the IC50 value (200 ng/ml). The
discrepancy between the IC values obtained from the efficacy
evaluations (RSA and MAGI) and those obtained from ChIP assay
could be explained by use of distinct experimental tools. For
example, the RSA measures DING-mediated inhibition of the
whole LTR promoter, while the ChIP assay is performed upon the
LTR probe encompassing only the NF-kB binding sequences. We
believe that minor structural differences between DING proteins
could impose unique physiological functions upon individual
DING variants, such as targeting several events in transcription
from the HIV-1 promoter, as reported for pDING [4,20,44].
Nonetheless, the inhibition of NF-kB/LTR binding seems to be a
common trait for all tested DING variants.
We indicated before that the eukaryotic genes encoding DING
proteins might originate from evolutionary conservation [53]. The
notable preservation of their structure and function could have its
origin in the selective pressure necessary to maintain successful
clearance of invading pathogens. Maintenance of these genes
throughout the process of evolution was likely related to the
retention and development of functions essential to survive the
pathogen invasion. These studies provide direct proof for this
hypothesis. DING homologues from distinctly diverse organisms
retain a structural and functional resemblance. The bacterial,
plant and human DING proteins blocked transcription of the
HIV-1 LTR promoter in cell-based assays suggesting that these
proteins might permeate the cell membrane or interact with a cell-
surface receptor in similar ways. The mechanism of X-DING-
CD4-cell membrane interactions and downstream effects of these
interactions is currently under investigation.
We believe that the LTR-blocking activity is, in part, a
consequence of a broad-spectrum DING-mediated mechanism
to block pathogen-induced activation of NF-kB-dependent pro-
moters [22,25,26]. This function becomes a strategic advantage in
the event of HIV disease. Nevertheless, the presence of such
proteins in some opportunistic pathogens (like Pseudomonas) may
interfere with this mechanism of innate immunity. In fact it has
been shown that X-DING-CD4 is able to block LPS-mediated
induction of NF-kB-dependent IL-8 transcription, and thus
interfere with the inflammatory process [25]. That means that it
is not to be excluded that bacteria may use their own DING
proteins in order to block the host’s inflammatory mechanism
upon invasion.
Figure 5. Human, plant and bacterial DING proteins block replication of HIV-1 in human PBLs. Replication of HIV-1 was assessed by
measurements of HIV-1 p24 core antigen (bars, right axis) and the viability of cells was established by the dye exclusion method (lines, left axis). The
results are representative of at least three separate measurements.
doi:10.1371/journal.pone.0069623.g005
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Previous study showed the ability of pDING to interfere with
other critical events involved in HIV-1 replication that include
association of C/EBPb with the HIV-1 genome, nuclear
localization of HIV-1 Tat, and phosphorylation of C-terminal
polymerase by pTEF [20]. Based on extensive sequence homol-
ogy, it is anticipated that the other members of the DING family
can also exert activities similar to pDING on the other events that
may impact LTR transcription and replication. In earlier studies,
we showed that some HIV-1-infected individuals might control
virus replication through the induction of X-DING-CD4 gene
activity [21], and new studies indicate that expression of X-DING-
CD4 mRNA is significantly higher in peripheral blood mononu-
clear cells (PBMCs) from elite HIV-1 controllers than in AIDS
patients or uninfected controls [54]. This alone indicates that X-
DING-CD4, and possibly HPBP, function as molecules of the
human innate immunity system, while their counterpart, the
pDING, may have a similar function in plants. The fact of pDING
isolation from plant callus tissue [4] indicates co-localization of this
DING protein within the injured tissue caused by pathogenic
invasion.
In summary, we conclude that DING proteins form a distinctive
group of highly conserved biomolecules with highly redundant
properties, some of which are directed to protective anti-microbial
function across the species. Four members of this family block
HIV-1 transcription and their role in cellular innate immunity
responses needs further investigation. DING proteins are also an
attractive target for drug development, in particular because none
of the existing components of antiretroviral therapy targets HIV-1
transcription.
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